治疗腹泻型肠易激综合征新药艾沙度林

发布时间：2018-01-30 01:21

本文关键词： 艾沙度林腹泻型肠易激综合征 mu阿片受体激动剂 delta阿片受体激动剂 kappa阿片受体激动剂　出处：《中国新药杂志》2017年04期 　论文类型：期刊论文

【摘要】：肠易激综合征(IBS)是常见的功能性胃肠道失调疾病,其中以腹泻型肠易激综合征(IBS-D)居多。但是,目前治疗的手段并不能满足临床需求,特效治疗药物仍然急缺。艾沙度林机制特殊,作用于3个靶点:分别为mu阿片受体激动剂、delta阿片受体拮抗剂、kappa受体激动剂,目前是该类机制中第一个也是唯一一个获批的药物,具有止泻和治疗腹痛的效果,且同时不产生便秘的不良反应。艾沙度林于2015年5月27日在FDA获得批准。本文对其药理作用、药动学、临床研究及不良反应方面做简要综述。
[Abstract]:Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder, in which diarrhea irritable bowel syndrome (IBS-D) is the majority. However, the current treatment methods can not meet the clinical needs. The specific therapeutic drugs are still in short supply, and the mechanism of Esartraline is special, and it acts on three targets: mu opioid receptor agonist, delta opioid receptor antagonist, kappa receptor agonist, respectively. Currently, it is the first and only approved drug of this kind, which has the effect of relieving diarrhea and treating abdominal pain. It was approved by FDA on May 27th 2015. The pharmacological action, pharmacokinetics, clinical research and adverse reactions of Astradil were reviewed in this paper.
【作者单位】：江苏奥赛康药业股份有限公司;
【分类号】：R975
【正文快照】： 肠易激综合征(irritable bowel syndrome,IBS)是一种慢性、持续或间歇发作、以腹痛或腹部不适为核心症状,伴随排便习惯改变和/或性状异常(腹泻、便秘)的功能性胃肠病变,且患者并无结构或生化异常。IBS患者人数众多,在亚洲国家的发病率为5%~10%[1]。2012年有数据显示,IBS高峰年

【参考文献】